Kowa Pharmaceuticals America
Medical illustration of the eye emphasizing ocular health

Newsroom

Press releases

  • AUGUST 27, 2026

    Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular Hypertension

  • JULY 1, 2026

    Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment

  • FEBRUARY 10, 2026

    Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026

Publications

  • NCX 470 Phase 3 Efficacy and Safety — Poster Presentation

  • Mechanisms of Optic Nerve Protection in Glaucoma — Review Article

  • Comparative Efficacy of Novel IOP-Lowering Agents in Open-Angle Glaucoma

Explore Our Products and Pipeline